All Stories

  1. Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review

    Article • March 2023, Taylor & Francis

    Robert Hoerr

  2. Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects

    Article • Frontiers in Pharmacology, April 2022, Frontiers

    Robert Hoerr

  3. <i>Ginkgo biloba</i> Extract EGb 761<sup>®</sup> Improves Central Vestibular Vertigo in Patients Undergoing Vestibular Exercises: A Randomised Placebo-Controlled Trial

    Article • Neuroscience &amp Medicine, January 2022, Scientific Research Publishing, Inc,

    Robert Hoerr

  4. Aqueous-ethanolic extracts of Curcuma longa and Withania somnifera improve memory in the dementia model

    Article • Journal of Research in Pharmacy, January 2022, ASOS Yayinevi

    Robert Hoerr

  5. EGb 761® Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer’s Dementia—Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial

    Article • Healthcare, December 2021, MDPI AG

    Robert Hoerr

  6. Ginkgo biloba extract EGb 761® alleviates neurosensory symptoms in patients with dementia: a meta-analysis of treatment effects on tinnitus and dizziness in randomized, placebo-controlled trials

    Article • Clinical Interventions in Aging, June 2018, Dove Medical Press

    Robert Hoerr

  7. Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial

    Article • Open Access Journal of Clinical Trials, January 2016, Dove Medical Press

    Robert Hoerr

  8. A retrospective classification of diagnoses in terms of DSM-5 for patients included in randomized controlled trials of Ginkgo biloba extract EGb 761®

    Article • European Archives of Psychiatry and Clinical Neuroscience, August 2015, Springer Science + Business Media

    Robert Hoerr

  9. Ginkgo biloba and Usage in Dementia

    Article • January 2015, Elsevier

    Robert Hoerr

  10. The NPI composite score is as sensitive to change as the frequency score in patients with MCI.

    Article • International Psychogeriatrics, July 2014, Cambridge University Press

    Robert Hoerr

  11. Efficacy and safety of Ginkgo biloba extract EGb 761 ® in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo‐controlled, double‐blind, multi‐center trial

    Article • International Journal of Geriatric Psychiatry, March 2014, Wiley

    Robert Hoerr

  12. SKT Short Cognitive Performance Test and Activities of Daily Living in Dementia

    Article • GeroPsych, January 2014, Hogrefe Publishing Group

    Dr. Mark Stemmler, Robert Hoerr

  13. Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety ofGinkgo bilobaExtract EGb 761 and Betahistine

    Article • International Journal of Otolaryngology, January 2014, Hindawi Publishing Corporation

    Robert Hoerr

  14. Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia

    Article • International Psychogeriatrics, November 2012, Cambridge University Press

    Professor Ralf Ihl, Robert Hoerr

  15. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg

    Article • Journal of Psychiatric Research, June 2012, Elsevier

    Robert Hoerr

  16. Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers

    Article • European Journal of Clinical Pharmacology, December 2011, Springer Science + Business Media

    Robert Hoerr

  17. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761®. Findings from a randomized controlled trial

    Article • Neuropsychiatric Disease and Treatment, April 2011, Taylor & Francis

    Professor Ralf Ihl, Robert Hoerr

  18. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial

    Article • International Journal of Geriatric Psychiatry, January 2010, Wiley

    Professor Ralf Ihl, Robert Hoerr

  19. Ginkgo biloba does not reduce incidence of dementia in elderly people

    Article • Evidence-Based Mental Health, July 2009, BMJ

    Robert Hoerr

  20. Ginkgo biloba extract EGb 761®, donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: A randomised, double-blind, exploratory trial

    Article • Aging & Mental Health, March 2009, Taylor & Francis

    Robert Hoerr

  21. Ginkgo biloba special extract EGb 761® in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial

    Article • Journal of Psychiatric Research, September 2007, Elsevier

    Robert Hoerr

  22. A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type

    Article • Current Alzheimer Research, December 2005, Bentham Science Publishers

    Robert Hoerr

  23. Treatment effects of EGb 761® and cholinesterase inhibitors – why available studies do not demonstrate superiority of the latter

    Article • Phytomedicine, August 2005, Elsevier

    Robert Hoerr

  24. Delay in progression of dependency and need of care of dementia patients treated with Ginkgo special extract EGb 761®

    Article • Wiener Medizinische Wochenschrift, November 2004, Springer Science + Business Media

    Robert Hoerr

  25. Ginkgo biloba Extract EGb 761® in Dementia: Intent-to-treat Analyses of a 24-week, Multi-center, Double-blind, Placebo-controlled, Randomized Trial

    Article • Pharmacopsychiatry, November 2003, Thieme Publishing Group

    Robert Hoerr

  26. Influence of the Severity of Cognitive Impairment on the Effect of the <i>Ginkgo biloba</i> Extract EGb 761<sup>®</sup> in Alzheimer’s Disease

    Article • Neuropsychobiology, January 2002, Karger Publishers

    Robert Hoerr

  27. KA 672-HCl, a Neuronal Activator Against Dementia: Tolerability, Safety, and Preliminary Pharmacokinetics after Single and Multiple Oral Doses in Healthy Male and Female Volunteers

    Article • The Journal of Clinical Pharmacology, April 1998, Wiley

    Robert Hoerr